Hunan Hansen Pharmaceutical Co Ltd (002412) — Working Capital to Net Assets Ratio
Hunan Hansen Pharmaceutical Co Ltd (002412) has a Working Capital to Net Assets ratio of 42.8% as of September 2025. Working capital of CN¥968.15 Million (current assets of CN¥1.25 Billion minus current liabilities of CN¥277.34 Million) is measured against net assets of CN¥2.26 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Hunan Hansen Pharmaceutical Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hunan Hansen Pharmaceutical Co Ltd Working Capital to Net Assets (2006–2024)
This chart shows how Hunan Hansen Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the ratio stands at 42.8%, reflecting working capital of CN¥968.15 Million against net assets of CN¥2.26 Billion CNY. Check Hunan Hansen Pharmaceutical Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Hunan Hansen Pharmaceutical Co Ltd (2006–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hunan Hansen Pharmaceutical Co Ltd from 2006 to 2024, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Hunan Hansen Pharmaceutical Co Ltd market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 36.5% | CN¥804.85 Million | CN¥2.20 Billion | CN¥1.12 Billion | CN¥318.32 Million | ▲ +9.0 pp |
| 2023 | 27.5% | CN¥540.65 Million | CN¥1.96 Billion | CN¥896.07 Million | CN¥355.42 Million | ▲ +1.9 pp |
| 2022 | 25.6% | CN¥485.17 Million | CN¥1.89 Billion | CN¥865.40 Million | CN¥380.24 Million | ▲ +15.0 pp |
| 2021 | 10.6% | CN¥184.30 Million | CN¥1.74 Billion | CN¥535.41 Million | CN¥351.11 Million | ▼ -5.4 pp |
| 2020 | 15.9% | CN¥254.03 Million | CN¥1.59 Billion | CN¥527.46 Million | CN¥273.43 Million | ▼ -0.9 pp |
| 2019 | 16.8% | CN¥257.34 Million | CN¥1.53 Billion | CN¥593.86 Million | CN¥336.52 Million | ▲ +11.4 pp |
| 2018 | 5.4% | CN¥73.56 Million | CN¥1.36 Billion | CN¥490.94 Million | CN¥417.38 Million | ▲ +2.5 pp |
| 2017 | 2.9% | CN¥35.16 Million | CN¥1.22 Billion | CN¥497.08 Million | CN¥461.93 Million | ▼ -3.9 pp |
| 2016 | 6.7% | CN¥84.87 Million | CN¥1.26 Billion | CN¥482.03 Million | CN¥397.16 Million | ▼ -35.5 pp |
| 2015 | 42.3% | CN¥529.76 Million | CN¥1.25 Billion | CN¥637.99 Million | CN¥108.23 Million | ▲ +3.1 pp |
| 2014 | 39.2% | CN¥452.19 Million | CN¥1.15 Billion | CN¥646.19 Million | CN¥194.00 Million | ▼ -2.8 pp |
| 2013 | 42.0% | CN¥465.75 Million | CN¥1.11 Billion | CN¥628.00 Million | CN¥162.25 Million | ▼ -37.7 pp |
| 2012 | 79.7% | CN¥769.43 Million | CN¥965.11 Million | CN¥842.66 Million | CN¥73.23 Million | ▼ -8.4 pp |
| 2011 | 88.1% | CN¥778.48 Million | CN¥883.65 Million | CN¥831.30 Million | CN¥52.82 Million | ▼ -2.7 pp |
| 2010 | 90.8% | CN¥816.41 Million | CN¥898.82 Million | CN¥863.26 Million | CN¥46.85 Million | ▲ +36.4 pp |
| 2009 | 54.4% | CN¥97.62 Million | CN¥179.51 Million | CN¥164.96 Million | CN¥67.34 Million | ▲ +15.7 pp |
| 2008 | 38.6% | CN¥50.33 Million | CN¥130.26 Million | CN¥135.00 Million | CN¥84.67 Million | ▲ +22.6 pp |
| 2007 | 16.0% | CN¥14.07 Million | CN¥87.77 Million | CN¥100.56 Million | CN¥86.49 Million | ▲ +46.1 pp |
| 2006 | -30.0% | CN¥-20.20 Million | CN¥67.28 Million | CN¥124.26 Million | CN¥144.46 Million | — |